Average Price Target: $9.25
▲ +112.64% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Quotient in the last 3 months. The average price target is $9.25, with a high forecast of $13.50 and a low forecast of $5.00. The average price target represents a 112.64% upside from the last price of $4.35.
The current consensus among 2 polled investment analysts is to buy stock in Quotient.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company is also developing microarray-based SARS-CoV-2 antibody test for use on the MosaiQ platform for COVID-19. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.